Netflix signs US broadcast deal with FIFA for the Women's World Cup in 2027 and 2031 GENEVA (AP) — Netflix has secured the U.S. broadcasting rights to the Women’s World Cup in 2027 and 2031 as the streaming giant continues its push into live sports. Graham Dunbar, The Associated Press Dec 20, 2024 10:47 AM Share by Email Share on Facebook Share on X Share on LinkedIn Print Share via Text Message FILE - Spain's Aitana Bonmati celebrates after scoring a goal, during the women's Group C match between Spain and Japan, at La Beaujoire Stadium, during the 2024 Summer Olympics Thursday, July 25, 2024, in Nantes, France. (AP Photo/Jeremias Gonzalez, File) GENEVA (AP) — Netflix has secured the U.S. broadcasting rights to the Women’s World Cup in 2027 and 2031 as the streaming giant continues its push into live sports. The deal announced Friday is the most significant FIFA has signed with a streaming service for a major tournament. The value was not given, though international competitions in women’s soccer have struggled to draw high-value offers. “Bringing this iconic tournament to Netflix isn’t just about streaming matches,” its chief content officer Bela Bajaria said in a statement. “It’s also about celebrating the players, the culture and the passion driving the global rise of women’s sport.” Netflix dipped into live sports last month with more than 60 million households watching a heavily hyped boxing match between retired heavyweight legend Mike Tyson and social media personality Jake Paul. Some viewers reported streaming problems , however. Netflix also will broadcast two NFL games on Christmas Day: the Kansas City Chiefs at the Pittsburgh Steelers and Baltimore Ravens at the Houston Texans. That’s part of a three-year deal announced in May. World Cups are typically broadcast on free-to-air public networks to reach the biggest audiences, and the last women's edition in 2023 earned FIFA less than 10% of the men's 2022 World Cup. FIFA president Gianni Infantino had publicly criticized public broadcasters , especially in Europe, for undervaluing offers to broadcast the 2023 tournament that was played in Australia and New Zealand. That tournament was broadcast by Fox in the U.S. “This agreement sends a strong message about the real value of the FIFA Women’s World Cup and the global women’s game,” Infantino said. The World Cup rights mark another major step in Netflix’s push into live programming. It’s recipe that Netflix has cooked up to help sell more advertising, a top priority for the company since it introduced a low-priced version of its streaming service that includes commercials two years ago. The ad-supported version is now the fastest growing part of Netflix’s service, although most of its 283 million worldwide subscribers till pay for higher-priced options without commercial. But Netflix is still trying to sell more ads to boost its revenue, which is expected to be about $30 billion. Netflix executives have predicted it might take two or three years before its ad sales become a major part of its revenue. Netflix expects to spend about $17 billion on programming this year — a budget that the Los Gatos, California, company once funneled almost entirely into scripted TV series and movies. But Netflix is now allocating a significant chunk of that money to sports and live events, a shift that has made it a formidable competitor to traditional media bidding for the same rights. FIFA will likely use the Netflix deal to drive talks with European broadcasters that likely will be hardball negotiations. Soccer finance expert Kieran Maguire, a co-host of The Price of Football podcast, suggested the deal was “a bit of a gamble" for FIFA and “saber-rattling” by Infantino. “(Netflix) get experience of football broadcasting, FIFA can say, ‘we are now partnering with a blue chip organization, so watch out you nasty Europeans,’” Maguire, an academic at the University of Liverpool, said in a telephone interview. FIFA and Infantino also want to raise the price of broadcast deals to help fund increased prize money and close the gender pay gap on the men’s World Cup. At the men’s 2022 World Cup in Qatar, the 32 team federations shared $440 million in prize money. For the women’s 2023 tournament , FIFA had a $152 million total fund for prize money, contributions to teams’ preparation costs and payments to players’ clubs. In FIFA’s financial accounts for 2023 , the soccer body reported total broadcasting revenue of $244 million. In the year of the men’s 2022 World Cup it was almost $2.9 billion. The next Women's World Cup will be a 32-team, 64-game tournament in 2027, played in Brazil from June 24-July 25. The U.S. originally bid jointly with Mexico. The 2031 host has not been decided, though the U.S. likely will bid for a tournament which FIFA is expected to try to expand to 48 teams. That would match the size of the 104-game format of the men's World Cup that debuts in 2026 in the U.S., Canada and Mexico. Spain won the 2023 Women's World Cup after the U.S. won the two previous titles — in France in 2019 and Canada in 2015. More than 25 million viewers in the U.S. watched the 2015 World Cup final, a 5-2 win over Japan, played in Vancouver, Canada, in a time zone similarly favorable to Brazil. FIFA tried to sign Apple+ to an exclusive global deal to broadcast the inaugural 32-team Club World Cup which is being played in 11 U.S. cities next June and July. Broadcast networks showed little interest in the FIFA club event that will now be broadcast for free on streaming service DAZN, which is building closer business ties to Saudi Arabia. Ahead of the next Women's World Cup, Netflix will "produce exclusive documentary series in the lead-up to both tournaments, spotlighting the world’s top players, their journeys and the global growth of women’s football,” FIFA said. ___ AP Technology Writer Michael Liedtke in San Francisco contributed to this report. ___ AP soccer: https://apnews.com/hub/soccer Graham Dunbar, The Associated Press See a typo/mistake? Have a story/tip? This has been shared 0 times 0 Shares Share by Email Share on Facebook Share on X Share on LinkedIn Print Share via Text Message Get your daily Victoria news briefing Email Sign Up More Soccer Expansion San Diego FC takes Ghanaian midfielder Manu Duah first in MLS SuperDraft Dec 20, 2024 11:30 AM Atlanta United brings back Ronny Deila to MLS as new coach Dec 20, 2024 10:44 AM New knockout format for European soccer competitions debuts with Conference League playoffs draw Dec 20, 2024 10:31 AMcat fishing 。

Task force report: Donald Trump assassination attempt in Butler was 'preventable'

Parents, states press Congress to act on kids online safety bill3 US Army soldiers arrested on human smuggling charges along the border with MexicoNone

NASHVILLE, Tenn. — The University of South Dakota women’s basketball team notched a season-high scoring output en route to a 79-69 victory over Dayton on Tuesday during the first of two games for the Coyotes at the Music City Classic. Grace Larkins and Alexi Hempe paced the Coyotes with big performances. Larkins matched a career-high with 34 points on 50% shooting from the field with seven rebounds as well. Meanwhile, Hempe scored a career-high 23 points in the matchup to go along with eight rebounds of her own. ADVERTISEMENT The Coyotes got out to an early advantage of 19-9 through the first quarter with a stifling defense that only allowed the Flyers to shoot 22% from the field in the opening 10 minutes. The advantage grew by halftime, with USD leading 41-29 at the intermission. Dayton was the team to come out of the locker room on the front to start the third quarter though. The Flyers began to close the gap, hitting as many field goals in the third quarter as they did in the first two combined. However, the Coyotes still held a 59-52 advantage thanks to seven points from Hempe in the final four minutes of the quarter. Larkins and Hempe stayed hot as the two combined for 13 of the Coyotes' 20 points in the fourth quarter as they went on to close out the Flyers for their third win of the season and third straight. For Dayton, Nicole Stephens led the way with 15 points, Arianna Smith was right behind with 14 points of her own, while Ivy Wolf also finished in double-figures with 13. USD (3-4) will finish out the Music City Classic against Arizona State at 11 a.m. Wednesday.By Michelle Marchante, Miami Herald (TNS) MIAMI — As her students finished their online exam, Arlet Lara got up to make a cafe con leche . Her 16-year-old son found her on the kitchen floor. First, he called Dad in a panic. Then 911. “I had a stroke and my life made a 180-degree turn,” Lara told the Miami Herald, recalling the medical scare she experienced in May 2020 in the early months of the COVID pandemic. “The stroke affected my left side of the body,” the North Miami woman and former high school math teacher said. Lara, an avid runner and gym goer, couldn’t even walk. “It was hard,” the 50-year-old mom said. After years of rehabilitation therapy and a foot surgery, Lara can walk again. But she still struggles with moving. This summer, she became the first patient in South Florida to get an implant of a new and only FDA-approved nerve stimulation device designed to help ischemic stroke survivors regain movement in their arms and hands. This first procedure was at Jackson Memorial Hospital in Miami. Lara’s rehab was at at the Christine E. Lynn Rehabilitation Center for The Miami Project to Cure Paralysis, part of a partnership between Jackson Health System and UHealth. Every year, thousands in the United States have a stroke , with one occurring every 40 seconds, according to the U.S. Centers for Disease Control and Prevention. The majority of strokes are ischemic, often caused by blood clots that obstruct blood flow to the brain. For survivors, most of whom are left with some level of disability, the Vivistim Paired VNS System, the device implanted in Lara’s chest, could be a game changer in recovery, said Dr. Robert Starke, a UHealth neurosurgeon and interventional neuroradiologist. He also serves as co-director of endovascular neurosurgery at Jackson Memorial Hospital, part of Miami-Dade’s public hospital system. Arlet Lara, the first patient in South Florida to get an FDA-approved nerve stimulation implant, right, runs into her rehabilitation neurology physician Dr. Gemayaret Alvarez, before her physical therapy appointment on Monday, Sept. 9, 2024, at Lynn Rehabilitation Center at Jackson Memorial Hospital. The implant is designed to help stroke survivors regain function in their arms. (Alie Skowronski/Miami Herald/TNS) Arlet Lara, the first patient in South Florida to get an FDA-approved nerve stimulation implant designed to help stroke survivors regain function in their arms, goes through exercises while her therapist activates the device during her physical therapy appointment on Monday, Sept. 9, 2024, at Lynn Rehabilitation Center at Jackson Memorial Hospital. The activation works as positive reinforcement to her muscles when she completes the exercise correctly. (Alie Skowronski/Miami Herald/TNS) Arlet Lara, the first patient in South Florida to get an FDA-approved nerve stimulation implant, does an exercise while Neil Batungbakal, rehabilitation therapist, activates the implant with the black trigger during her physical therapy appointment on Monday, Sept. 9, 2024, at Lynn Rehabilitation Center at Jackson Memorial Hospital. The implant is designed to help stroke survivors regain function in their arms. The activation works as positive reinforcement to her muscles when she completes the exercise correctly. (Alie Skowronski/Miami Herald/TNS) Arlet Lara, the first patient in South Florida to get an FDA- approved nerve stimulation implant, does an exercise while Neil Batungbakal, rehabilitation therapist, activates the implant with the black trigger during her physical therapy appointment on Monday, Sept. 9, 2024, at Lynn Rehabilitation Center at Jackson Memorial Hospital. Arlet Lara, the first patient in South Florida to get an FDA-approved nerve stimulation implant, right, runs into her rehabilitation neurology physician Dr. Gemayaret Alvarez, before her physical therapy appointment on Monday, Sept. 9, 2024, at Lynn Rehabilitation Center at Jackson Memorial Hospital. The implant is designed to help stroke survivors regain function in their arms. (Alie Skowronski/Miami Herald/TNS) The Vivistim Paired VNS System is a small pacemaker-like device implanted in the upper chest and neck area. Patients can go home the same day. The U.S. Food and Drug Administration approved the stroke rehabilitation system in 2021 to be used alongside post-ischemic stroke rehabilitation therapy to treat moderate to severe mobility issues in hands and arms. Lara’s occupational therapist can activate the device during rehabilitation sessions to electrically stimulate the vagus nerve, which runs from the brain down to the abdomen and regulates various parts of the body’s nervous system. The electrical stimulation rewires the brain to improve a stroke survivor’s ability to move their arms and hands. Lara also has a magnet she can use to activate the device when she wants to practice at home. Her therapy consists of repetitive tasks, including coloring, pinching cubes and grabbing and releasing cylindrical shapes. After several weeks of rehabilitation therapy with the device, Lara has seen improvement. “Little by little, I’m noticing that my hand is getting stronger. I am already able to brush my teeth with the left hand,” she told the Miami Herald in September. Since then, Lara has finished the initial six-week Vivitism therapy program, and is continuing to use the device in her rehabilitation therapy. She continues to improve and can now eat better with her left hand and can brush her hair with less difficulty, according to her occupational therapist, Neil Batungbakal. Lara learned about the device through an online group for stroke survivors and contacted the company to inquire. She then connected them with her Jackson medical team. Now a year later, the device is available to Jackson patients. So far, four patients have received the implant at Jackson. Starke sees the device as an opportunity to help bring survivors one step closer to regaining full mobility. Strokes are a leading cause of disability worldwide. While most stroke survivors can usually recover some function through treatment and rehabilitation, they tend to hit a “major plateau” after the first six months of recovery, he said. Vivistim, when paired with rehabilitation therapy, could change that. Jackson Health said results of a clinical trial published in the peer-reviewed medical journal The Lancet in 2021 showed that the device, “when paired with high-repetition, task-specific occupational or physical therapy, helps generate two to three times more hand and arm function for stroke survivors than rehabilitation therapy alone.” The device has even shown to benefit patients 20 years from their original stroke, according to Starke. “So now a lot of these patients that had strokes 10-15 years ago that thought that they would never be able to use their arm in any sort of real functional way are now able to have a real meaningful function, which is pretty tremendous,” Starke said. Vivistim’s vagus-nerve stimulation technology was developed by researchers at the University of Texas at Dallas’ Texas Biomedical Device Center and is being sold commercially by Austin-based MicroTransponder, a company started by university graduates. Similar devices are used to treat epilepsy and depression . For Lara, the device is a new tool to help her recovery journey. “Everything becomes a challenge so we are working with small things every day because I want to get back as many functions as possible,” Lara said. Patients interested in Vivistim should speak with their doctor to check their eligibility. The FDA said patients should make sure to discuss any prior medical history, including concurrent forms of brain stimulation, current diathermy treatment, previous brain surgery, depression, respiratory diseases and disorders such as asthma, and cardiac abnormalities. “Adverse events included but were not limited to dysphonia (difficulty speaking), bruising, falling, general hoarseness, general pain, hoarseness after surgery, low mood, muscle pain, fracture, headache, rash, dizziness, throat irritation, urinary tract infection and fatigue,” the FDA said. MicroTransponder says the device is “covered by Medicare, Medicaid, and private insurance with prior authorization on a case-by-case basis.” To learn more about the device, visit vivistim.com. ©2024 Miami Herald. Visit at miamiherald.com. Distributed by Tribune Content Agency, LLC.Major supermarket slashes price of festive fizz to just £4.75 – but you’ll have to be quick as fans rush to stores